Le Lézard
Classified in: Science and technology, Business, Covid-19 virus
Subjects: PDT, ACC, CXP

Seedtag Raises $40m in Series B Funding Led By Oakley Capital for US Expansion


MADRID, Sept. 14, 2021 Seedtag, the leader in contextual advertising in EMEA and LATAM, has announced today that it has secured $40m in Series B funding. Led by Oakley Capital, the funding round - which was also participated in by Adara Ventures and All Iron Ventures - follows on from the $5.2m raise in Seedtag's Series A funding round in 2017.

 

Seedtag Raises $40m in Series B Funding Led

 

Oakley Capital is a leading mid-market growth equity investor in Europe with more than 4B$ under management and an outstanding track record taking market leaders to the next level.

Seedtag aims to continue moving forward in its mission to be the global contextual advertising partner for brands and agencies. Already the leader in contextual advertising in EMEA and LATAM, the company intends to use the raised funds to now expand into the US market and continue investing in its contextual AI technology. LionTree acted as an exclusive financial advisor to Seedtag shareholders in a bilateral deal with Oakley.

The advertising industry is undergoing a significant change in terms of targeting audiences. In the next few years, it is expected that brands will no longer be able to leverage third-party cookies to reach target audiences.

Without the use of cookies, Seedtag is best positioned to provide a deep understanding of consumers' interests, build a contextual strategy based on data and gather a range of insights that can help brands improve their results.

Seedtag achieved significant growth in 2020 following further development and improvement of product capabilities. The organisation produced organic year-on-year growth of 25% even under COVID-19 impact, reaching revenues of $50m in 2020, and with a further 60% growth forecast for 2021 ($80 million).

Peter Dubens, Managing Partner at Oakley Capital, states: "Oakley's investment in Seedtag demonstrates our continuing ability to source proprietary deals from across our network and in attractive sectors. An increasing focus on consumer privacy and brand safety is driving growth in contextual advertising, and we believe Seedtag is well-placed to harness this exciting opportunity thanks to a combination of best-in-class technology, strong commercial relationships and an impressive management team."

Albert Nieto, co-CEO of Seedtag, said: "Oakley's investment reinforces our strategy to create a worldwide leader in contextual advertising. We are looking forward to offering US brands and publishers our contextual solutions."

Rocío Martínez de Carlos
PR Coordinator at Seedtag
[email protected]  
+34 628533468

Photo - https://mma.prnewswire.com/media/1613053/Seedtag_Series_B_Funding.jpg
Logo - https://mma.prnewswire.com/media/1613054/Seedtag_Logo.jpg

 

Seedtag Logo

 


These press releases may also interest you

at 08:05
Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in a pilot study collecting patient-generated health data (PGHD) during proton radiotherapy for lung cancer in...

at 08:05
AVI Systems, the largest global audiovisual and unified collaboration systems integrator, today announced the launch of a new customer-focused offering called the AVI Experience. This initiative provides prospects and customers interested in...

at 08:05
Elite Robots, a leading supplier of collaborative robots, will exhibit its enriched range of cobots and all-in-one solutions at the upcoming Automate Show (May 6-9, Chicago), at booth 4255. After a successful 2023, in which Elite Robots experienced...

at 08:05
Edgio, the platform of choice for security, speed and simplicity at the edge, today announced the release of its Client-Side Protection solution. Designed to monitor scripts and APIs on the browser-side to prevent malicious code from exfiltrating...

at 08:05
Today, Stellar Cyber, the innovator of Open XDR, announced a new partnership with Acronis, a global leader in cybersecurity and data protection, to deliver an optimized threat detection and response solution enabling MSPs to protect on-premises,...

at 08:05
Roivant and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for...



News published on and distributed by: